The integration of wearable technology into early-phase cancer trials represents a pivotal moment in oncology research, offering the ability to transform how we assess and predict clinical outcomes for patients. Traditional methods such as the Karnofsky Performance Status (developed in 1948) and ECOG Performance Status (introduced in 1982) have been the gold standard for decades. […]
Randomized clinical trials (RCTs) began in the 1940s with streptomycin’s evaluation against tuberculosis. Since then, RCTs have been the foundation of clinical trial design, ensuring therapies reach patients safely. For decades, oncology trials followed a set pattern: drugs were tested in preclinical models, followed by dose escalation to assess safety, toxicity, and efficacy compared to
Why Adaptive Clinical Trials in Community Settings are the Future of Cancer Research Read More »
Accelerating Targeted Cancer Therapy Trials: Perspectives from START Key Highlights Significant increase in FDA-approved targeted cancer therapies over the past decade. Low prevalence of specific mutations and variable toxicities of targeted therapies are important challenges to consider when starting a trial. Selecting sites with expertise is crucial to timely completion of trials with accurate reporting.
Community-Based Clinical Trials: A Catalyst for Advancing Targeted Therapies Read More »
The START Center for Cancer Research represents a global team of leading investigators in medical oncology, driven by a commitment to improving clinical trial access for patients treated in community oncology centers. Emiliano Calvo, MD, PhD, and Victor Moreno, MD, PhD, serve as Directors of Clinical Research at START Madrid-CIOCC and START Madrid-FJD, respectively. As
Driving Oncology Research Progress Through Access to Early-Phase Trials Read More »
Varius nec, elit turpis amet, proin ut sed nec donec auctor dolor arcu, sollicitudin.
